{
    "nct_id": "NCT03875287",
    "official_title": "A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors",
    "inclusion_criteria": "* Participants must have advanced, unresectable, and/or metastatic solid tumor malignancy that is histologically or cytologically confirmed.\n* Patients must have received at least 2 lines of therapy in the advanced/metastatic setting (if 2 lines exist) and have no other possible therapies or refuse therapies that have shown clinical benefit for their condition.\n* ECOG performance status <1\n* Ability to understand and the willingness to sign a written informed consent document.\n* Patients must have measurable disease\n* Ability to swallow oral medications\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Participants who have had chemotherapy or radiotherapy within 3 weeks\n* Participants may not be receiving any other investigational agents.\n* Active hepatitis B or hepatitis C infection.\n* Active or untreated gastric or duodenal ulcer\n* Symptomatic bowel obstruction within 3 months prior to screening visit.\n* Symptomatic ascites in the last 4 weeks\n\nOther protocol defined inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}